MX2018012564A - Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata. - Google Patents

Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata.

Info

Publication number
MX2018012564A
MX2018012564A MX2018012564A MX2018012564A MX2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A MX 2018012564 A MX2018012564 A MX 2018012564A
Authority
MX
Mexico
Prior art keywords
prostate cancer
reducing
progression
preventing
peptide
Prior art date
Application number
MX2018012564A
Other languages
English (en)
Inventor
Averback Paul
Original Assignee
Nymox Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nymox Corp filed Critical Nymox Corp
Publication of MX2018012564A publication Critical patent/MX2018012564A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

Las modalidades incluyen prevenir o reducir el avance del cáncer de próstata en mamíferos susceptibles de desarrollar cáncer de próstata y reducir la incidencia de cáncer de próstata detectado clínicamente, mediante el uso de composiciones que contienen compuestos basados en péptidos de la cadena neural pequeños en función de la SEQ. ID. NO. 66 (IDQQVLSRIKLEIKRCL) y un portador farmacéuticamente aceptable. La modalidad incluye, de modo no taxativo, administrar los compuestos de forma intramuscular, por vía oral, intravenosa, intraprostática, intratecal, intratumoral, intranasal, tópica, transdérmica, etc., ya sea solo o conjugado con un portador a un mamífero que lo necesita.
MX2018012564A 2016-06-17 2017-06-19 Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata. MX2018012564A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/185,344 US10183058B2 (en) 2016-06-17 2016-06-17 Method of preventing or reducing the progression of prostate cancer
PCT/IB2017/053626 WO2017216779A1 (en) 2016-06-17 2017-06-19 Neural thread peptide for preventing or reducing the progression of prostate cancer

Publications (1)

Publication Number Publication Date
MX2018012564A true MX2018012564A (es) 2019-02-13

Family

ID=59315668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012564A MX2018012564A (es) 2016-06-17 2017-06-19 Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata.

Country Status (13)

Country Link
US (1) US10183058B2 (es)
EP (1) EP3432907B1 (es)
JP (1) JP6883048B2 (es)
KR (1) KR102169213B1 (es)
CN (2) CN116785403A (es)
AU (1) AU2017283820B2 (es)
BR (1) BR112018071118A2 (es)
CA (1) CA3020252C (es)
MX (1) MX2018012564A (es)
NZ (1) NZ746758A (es)
RU (1) RU2719598C1 (es)
WO (1) WO2017216779A1 (es)
ZA (1) ZA201806469B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10835538B2 (en) 2018-03-28 2020-11-17 Nymox Corporation Method of treating benign prostatic hyperlasia with antibiotics
US20200061150A1 (en) 2018-08-23 2020-02-27 Nymox Corporation Method of inducing selective prostate glandular pharmaco-ablation with sparing of nerves and preservation of sexual function
US20200360466A1 (en) 2019-05-13 2020-11-19 Nymox Corporation Method of improving lower urinary tract symptoms
US11298400B2 (en) 2019-05-13 2022-04-12 Nymox Corporation Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
US11278588B2 (en) 2019-05-13 2022-03-22 Nymox Corporation Method of treating lower urinary tract symptoms with fexapotide triflutate
US11331374B2 (en) 2019-07-31 2022-05-17 Nymox Corporation Focal treatment of prostate cancer
US11231421B2 (en) * 2019-07-31 2022-01-25 Nymox Corporation Methods of treating multifocal cancer

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4329364A (en) 1974-09-11 1982-05-11 Schering Corporation Antiandrogenic agents and methods for the treatment of androgen dependent disease states
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
DE2817157A1 (de) 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
FR2465486A1 (fr) 1979-09-21 1981-03-27 Roussel Uclaf Nouvelle application utilisant la lh-rh ou des agonistes
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3121153A1 (de) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie"
US4457489A (en) 1981-07-13 1984-07-03 Gilmore Samuel E Subsea fluid conduit connections for remote controlled valves
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
CA1310924C (en) 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5158881A (en) 1987-11-17 1992-10-27 Brown University Research Foundation Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US5672344A (en) 1987-12-30 1997-09-30 The Regents Of The University Of Michigan Viral-mediated gene transfer system
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CA2006332C (en) 1988-12-21 2003-04-08 Suzanne De La Monte Method of detecting neurological disease or dysfunction
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
JPH06256387A (ja) 1991-06-14 1994-09-13 Suetsuna Yoko 新規なペプチド、その製法およびそれを有効成分とする 血圧降下剤
ES2312913T3 (es) 1993-04-20 2009-03-01 The General Hospital Corporation Expresion genica de la proteina de la cadena neural y deteccion de la enfermedad de alzheimer.
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
KR100357839B1 (ko) 1994-03-07 2003-08-02 더 다우 케미칼 캄파니 생체활성및/또는표적화된덴드리머콘쥬게이트
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
EP0832269A1 (en) 1995-06-07 1998-04-01 Baylor College Of Medicine Nucleic acid transporters for delivery of nucleic acids into a cell
BR9711795A (pt) 1996-03-26 2000-06-06 Razvant T Radulescu Peptìdeos tendo propriedades antiproliferativas
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
AU749348B2 (en) 1997-02-26 2002-06-27 General Hospital Corporation, The Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's disease
WO1999019347A1 (en) 1997-10-10 1999-04-22 Astrazeneca Ab Synthetic genes with immunomodulatory effects
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
WO2000034477A2 (en) 1998-12-11 2000-06-15 Incyte Pharmaceuticals, Inc. Neuron-associated proteins
JP2002542766A (ja) 1999-03-12 2002-12-17 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
AU3628600A (en) 1999-03-19 2000-10-09 Human Genome Sciences, Inc. 46 human secreted proteins
EP1171462A2 (en) 1999-03-26 2002-01-16 Human Genome Sciences, Inc. 49 human secreted proteins
JP2002539842A (ja) 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４５個のヒト分泌タンパク質
JP2003535570A (ja) 1999-03-26 2003-12-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５０個のヒト分泌タンパク質
CN1300779A (zh) 1999-12-22 2001-06-27 上海博德基因开发有限公司 一种新的多肽－人神经元线蛋白17和编码这种多肽的多核苷酸
WO2002000718A2 (en) 2000-06-26 2002-01-03 Millennium Pharmaceuticals, Inc. A human calcium channel protein and uses thereof
US7259232B1 (en) * 2000-10-27 2007-08-21 Nymox Pharmaceutical Corporation Preferred segments of neural thread protein
CA2325666A1 (fr) 2000-12-01 2002-06-01 Institut Pasteur Peptides immunogeniques mutes derives de r9m, polynucleotides les codants et leurs usages therapeutiques
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
KR100632903B1 (ko) 2001-03-08 2006-10-13 니목스 파마슈티칼스 코포레이션 신경 사 단백질을 사용하여 종양 및 세포의 제거 또는파괴를 필요로 하는 다른 증상을 치료하는 방법
BR0209630A (pt) 2001-05-16 2004-03-30 Nymox Corp Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais
CN1582301A (zh) 2001-05-25 2005-02-16 尼莫克斯股份有限公司 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽
MXPA04000561A (es) * 2001-07-19 2005-02-17 Nymox Corp Peptidos eficaces en el tratamiento de tumores y otras condiciones que requieren la remocion o destruccion de celulas.
US7317077B2 (en) * 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7642063B2 (en) 2004-05-19 2010-01-05 Auburn University Methods for targeting and killing glioma cells
US8067378B2 (en) * 2006-02-28 2011-11-29 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
JP2009529503A (ja) * 2006-03-10 2009-08-20 ナイモックス コーポレーション 神経糸状タンパク質由来ペプチドを用いて癌を予防するまたはその危険度または発生率を減少させる方法
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US9243035B2 (en) 2013-11-26 2016-01-26 Nymox Corporation Peptides effective in the treatment of conditions requiring the removal or destruction of cells
US9856722B2 (en) 2014-03-14 2018-01-02 General Electric Company Methods and systems for controlling voltage switching
US20160215031A1 (en) 2015-01-27 2016-07-28 Nymox Pharnaceutical Corporation Method of treating disorders requiring destruction or removal of cells
JP6256387B2 (ja) 2015-03-09 2018-01-10 株式会社豊田自動織機 電動圧縮機

Also Published As

Publication number Publication date
CN116785403A (zh) 2023-09-22
AU2017283820B2 (en) 2019-09-26
KR102169213B1 (ko) 2020-10-23
CA3020252A1 (en) 2017-12-21
CA3020252C (en) 2022-07-26
KR20180124080A (ko) 2018-11-20
US20170360885A1 (en) 2017-12-21
NZ746758A (en) 2022-07-01
WO2017216779A1 (en) 2017-12-21
CN109310732A (zh) 2019-02-05
CN109310732B (zh) 2023-07-21
EP3432907B1 (en) 2019-10-16
US10183058B2 (en) 2019-01-22
BR112018071118A2 (pt) 2019-02-26
ZA201806469B (en) 2020-11-25
AU2017283820A1 (en) 2018-10-18
JP6883048B2 (ja) 2021-06-02
EP3432907A1 (en) 2019-01-30
JP2019523751A (ja) 2019-08-29
RU2719598C1 (ru) 2020-04-21

Similar Documents

Publication Publication Date Title
MX2018012564A (es) Peptido de la cadena neural para prevenir o reducir el avance de cancer de prostata.
MX2019002698A (es) Metodo para mitigar o prevenir el empeoramiento o la progresion sintomas de hpb.
MX2017009802A (es) Metodo para tratar desordenes que requieren la destruccion o retiro de celulas utilizando un peptido derivado de una proteina de hebra neural.
MA43283B1 (fr) Composition pour le traitement du cancer
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
MX2021013163A (es) Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral.
NO20093064L (no) Templatfikserte peptidhermere
MX2019010394A (es) Composiciones y metodos para mejorar la funcion sexual.
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
AU2024201828A1 (en) Methods of treating and/or preventing actinic keratosis
MX2019006515A (es) Composiciones que comprenden peptido wkdeagkplvk.
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2021004883A (es) Metodos y composiciones para tratar apnea del sue?o.
MX2019001209A (es) Metodo para evitar o reducir la incidencia de la retencion urinaria aguda.
AR111760A1 (es) Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
EP4219534A3 (en) Methods for treatment of and prophylaxis against inflammatory disorders
WO2019168897A3 (en) Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
WO2020212514A8 (en) Peptides in combination with immune checkpoint inhibitors for use in treatment of cancer
MX2022004910A (es) Metodos de tratamiento de los sintomas del trastorno del espectro autista.
MX2021012824A (es) Métodos para tratar el prurito.
WO2020012478A3 (en) Peptide compounds and therapeutic uses of same
WO2015183984A3 (en) Therapeutic compositions including tocopherol and uses thereof
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof
MX2018011675A (es) Composicion farmaceutica que comprende un fragmento fab' pegilado de anticuerpo anti-ngf humano.
MX2021013874A (es) Metodo para mejorar los sintomas del tracto urinario inferior.